Neogen (NEOG) Gross Profit Margin starting from the first quarter 2026 to first quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Neogen Corporation  (NASDAQ: NEOG)


Neogen's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NEOG Gross Profit Margin (Aug 31 2026)
Q1 		(May 31 2026)
Q4 		(Feb 28 2026)
Q3 		(Nov 30 2025)
Q2 		(Aug 31 2025)
Q1
Y / Y Revenue Change 6.67 %
Seq. Revenue Change -1.17 %
Revenue In Millions $222.90
Gross Profit Margin 47.38 %
Gross Profit Margin Total Ranking # 1826
Gross Profit In Millions $105.60
Y / Y Gross Profit Change 11.19 %
Seq. Gross Profit Change -2.04 %


Commenting First Quarter 2026 Gross Profit Margin
Neogen Corporation experienced contraction in Gross Profit by -2.04 % to $223 millions and Revenue by -1.17 %, while Gross Profit Margin fell to 47.38 %, below company*s average Gross Profit Margin.


Observing first quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 4 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1826, from total ranking in the previous quarter at 1948.
Learn about Gross Margin
NEOG's Gross Profit Margin first quarter 2026 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 5
Healthcare Sector # 327
Overall # 1810

Gross Profit Margin Statistics
High Average Low
53.82 % 48.12 % 40.93 %
(Nov 30 2012)   (May 31 2025)


NEOG Gross Income Trends • More of NEOG's Profitabilty Ratios • NEOG Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
NEOG's Cumulative Gross Profit Margin
In Vitro & In Vivo Diagnostic Substances Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
NEOG's Gross Profit Margin Profitability versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for NEOG's Competitors
Gross Profit Margin Profit Margin for Neogen's Suppliers
Gross Profit Margin Profit Margin for NEOG's Customers

You may also want to know
NEOG's Annual Growth Rates NEOG's Profitability Ratios NEOG's Asset Turnover Ratio NEOG's Dividend Growth
NEOG's Roe NEOG's Valuation Ratios NEOG's Financial Strength Ratios NEOG's Gross Profit Growth
NEOG's Roa NEOG's Inventory Turnover Ratio NEOG's Growth Rates NEOG's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Aug 31 2026, within In Vitro & In Vivo Diagnostic Substances Industry Gross Profit MarginAug 31 2026 MRQ Gross ProfitAug 31 2026 MRQ Revenue
Myriad Genetics Inc   67.93 %$ 137.700  Millions$ 202.700  Millions
Idexx Laboratories Inc  62.94 %$ 764.298  Millions$ 1,214.237  Millions
Lantheus Holdings Inc   62.43 %$ 243.412  Millions$ 389.913  Millions
Neogen Corporation  47.38 %$ 105.600  Millions$ 222.900  Millions
Quidelortho Corp  46.79 %$ 289.600  Millions$ 618.900  Millions
Alpha Teknova Inc   37.99 %$ 4.826  Millions$ 12.704  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.